×
CorMedix Inc EBIT 2011-2024 | CRMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
CorMedix Inc ebit from 2011 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
CorMedix Inc EBIT 2011-2024 | CRMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
CorMedix Inc ebit from 2011 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$155.8B
Bristol Myers Squibb (BMY)
$118.1B
Vertex Pharmaceuticals (VRTX)
$116B
Gilead Sciences (GILD)
$111.9B
CSL (CSLLY)
$86.5B
Regeneron Pharmaceuticals (REGN)
$81.8B
GSK (GSK)
$69.8B
Argenex SE (ARGX)
$35.7B
Alnylam Pharmaceuticals (ALNY)
$31.8B
BioNTech SE (BNTX)
$25.9B
Biogen (BIIB)
$23B
Illumina (ILMN)
$21.7B
BeiGene (BGNE)
$18.9B
Moderna (MRNA)
$14.7B
Incyte (INCY)
$13.6B
Genmab (GMAB)
$13.5B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.3B
Vaxcyte (PCVX)
$11B
Sarepta Therapeutics (SRPT)
$10.6B
Exelixis (EXEL)
$9.9B
Exact Sciences (EXAS)
$9.8B
QIAGEN (QGEN)
$9.7B
Revolution Medicines (RVMD)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$9.1B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$7.9B
Ascendis Pharma (ASND)
$7.4B